A Randomized, Double-blind, Single Ascending Dose, Safety, Tolerability, Pharmacokinetics Study of CTP-730 in Healthy Volunteers
Latest Information Update: 14 Jan 2020
At a glance
- Drugs CTP 730 (Primary)
- Indications Cancer; Inflammation
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Concert Pharmaceuticals
- 28 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
- 12 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.